Vericiguat in Heart Failure

Vericiguat in Heart Failure: Mechanism, Evidence, Dosing, and Clinical Positiom

Introduction

Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator approved for patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) who have had recent worsening heart failure despite guideline-directed medical therapy (GDMT). It targets the nitric oxide–sGC–cyclic GMP pathway, which is impaired in advanced heart failure.

This article provides a clinically focused, guideline-oriented review of vericiguat for practicing physicians and cardiology trainees.

---

Pathophysiologic Rationale

In chronic HFrEF:

Endothelial dysfunction reduces nitric oxide (NO) bioavailability

Oxidative stress impairs soluble guanylate cyclase activity

Reduced cyclic GMP (cGMP) leads to:

Increased vascular tone

Myocardial stiffness

Fibrosis

Progressive ventricular remodeling

Vericiguat directly stimulates soluble guanylate cyclase and enhances its sensitivity to endogenous NO, restoring cGMP signaling even when NO levels are low.

Result:

Vasodilation

Improved myocardial relaxation

Reduction in adverse remodeling

---

Mechanism of Action

Vericiguat:

1. Directly stimulates soluble guanylate cyclase (NO-independent action)

2. Sensitizes sGC to endogenous nitric oxide

3. Increases intracellular cyclic GMP

4. Promotes vasodilation and antifibrotic effects

Unlike nitrates, it does not rely solely on nitric oxide availability.

---

Approved Indication

Vericiguat is indicated in:

Symptomatic chronic HFrEF (NYHA class II–IV)

Left ventricular ejection fraction ≤ 45%

Recent worsening heart failure:

Hospitalization for HF, or

Need for IV diuretics

It is used in addition to standard GDMT.

---

Evidence: The VICTORIA Trial

Trial population:

High-risk HFrEF patients

Recent decompensation

Elevated NT-proBNP

Key findings:

Significant reduction in composite endpoint:

Cardiovascular death

Heart failure hospitalization

Absolute risk reduction modest but clinically meaningful

Benefit particularly relevant in recently destabilized patients

Important point: This was a very high-risk population, with event rates higher than in PARADIGM-HF or DAPA-HF trials.

---

Dosing Strategy

Initial dose:

2.5 mg once daily with food

Titration:

Increase every 2 weeks:

5 mg once daily

Target dose: 10 mg once daily

Dose adjustment:

Based on blood pressure tolerance

Avoid aggressive titration in hypotensive patients

---

Contraindications

Vericiguat is contraindicated in:

Pregnancy (teratogenic potential)

Concomitant use with:

Long-acting nitrates

PDE-5 inhibitors (e.g., sildenafil)

Other soluble guanylate cyclase stimulators (e.g., riociguat)

Combination increases risk of profound hypotension.

---

Adverse Effects

Common adverse effects include:

Hypotension

Syncope

Anemia

Compared to other heart failure drugs:

Minimal impact on renal function

No significant hyperkalemia signal

---

Monitoring

Routine monitoring includes:

Blood pressure

Hemoglobin

Standard heart failure labs (renal function, electrolytes)

No special laboratory monitoring beyond usual HF care is required.

---

Position in Guideline-Directed Medical Therapy

Vericiguat is not first-line therapy.

It is considered after foundational quadruple therapy:

1. ACE inhibitor / ARB / ARNI

2. Evidence-based beta-blocker

3. Mineralocorticoid receptor antagonist (MRA)

4. SGLT2 inhibitor

Best suited for:

Patients with recurrent HF hospitalization

Persistent high NT-proBNP

Advanced but ambulatory HFrEF

Those stabilized after recent decompensation

It is particularly useful in patients who remain high risk despite optimized therapy.

---

How Vericiguat Differs from Other HF Drugs

Compared with ARNI:

ARNI works via neprilysin inhibition and RAAS blockade

Vericiguat targets cGMP signaling directly

Compared with SGLT2 inhibitors:

SGLT2 inhibitors provide metabolic and renal benefits

Vericiguat primarily reduces recurrent HF events in high-risk patients

Compared with ivabradine:

Ivabradine targets heart rate

Vericiguat works at the vascular and myocardial signaling level

---

Practical Clinical Pearls

Ideal candidate: recently hospitalized HFrEF patient on optimized GDMT

Start low and titrate carefully in borderline BP patients

Do not combine with nitrates or PDE-5 inhibitors

Expect modest but meaningful reduction in HF hospitalization

Not a substitute for foundational HF therapies

---

Summary

Vericiguat represents a mechanistically distinct addition to the therapeutic armamentarium for HFrEF. By targeting the nitric oxide–sGC–cGMP pathway, it provides incremental benefit in high-risk patients with recent decompensation.

While not a first-line agent, it plays an important role in advanced HFrEF management, particularly in patients with persistent vulnerability to hospitalization despite optimized guideline-directed therapy.

In contemporary heart failure practice, vericiguat is best viewed as a risk-reduction strategy for the recently destabilized HFrEF patient.